AI Article Synopsis
- Tumour lysis syndrome (TLS) is a rare but serious complication that can occur after chemotherapy for solid tumours, due to rapid tumour cell death.
- Symptoms of TLS include metabolic imbalances and signs of kidney failure, which require prompt treatment through rehydration and fixing the metabolic issues.
- This case study highlights the first recorded instance of TLS in a patient with metastatic gastrointestinal stromal tumour treated with imatinib mesylate.
Article Abstract
Tumour lysis syndrome (TLS) is a rare side effect of chemotherapy for solid tumours. It describes the metabolic derangements following rapid and extensive tumour cell death following a good response to chemotherapy. Symptoms are those of metabolic derangement and renal failure. Treatment involves rehydration and correction of metabolic abnormalities. TLS should be considered in high risk groups. We report a case of TLS in a patient with metastatic gastrointestinal stromal tumour treated with imatinib mesylate. To our knowledge, this is the first reported case.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2225466 | PMC |
| http://dx.doi.org/10.1155/2007/82012 | DOI Listing |
Publication Analysis
Top Keywords
tumour lysis
8
lysis syndrome
8
patient metastatic
8
metastatic gastrointestinal
8
gastrointestinal stromal
8
stromal tumour
8
tumour treated
8
imatinib mesylate
8
tumour
5
syndrome occurring
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!